Q-omics provides the consensus-scored FAM214A profile across patient tissues and cancer cell-line models. FAM214A expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAM214A is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, FAM214A RNA expression shows 22,160 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where FAM214A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM214A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM214A survival associations across molecular data types. FAM214A RNA expression shows survival associations in the most cancer types (27), followed by mutation status (11) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM214A RNA expression–survival associations across cancer types. High FAM214A expression shows favorable associations in KIRC, BRCA, LIHC, HNSC, LGG and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FAM214A RNA expression.
This table summarizes FAM214A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM214A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM214A shows lower tumor expression in COAD, HNSC, THCA, LUSC and READ and higher tumor expression in KIRC. The COAD box plot shows higher FAM214A RNA expression in normal versus tumor tissue (log2 FC = −1.011, t-test p < 0.001).
This table shows molecular features associated with FAM214A in patient tissues and cancer cell lines. In patient samples, FAM214A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM214A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
